UNLABELLED: (124)I PET/CT images from differentiated thyroid cancer patients were retrospectively analyzed to assess the relationship between absorbed radiation dose (AD) to lesions and their response after radioiodine therapy. METHODS: Patients received serial (124)I PET/CT scans before and after their first radioiodine treatment. The pretherapy PET data were used to segment the lesion volumes and to predict the therapy-delivered ADs after administration of the therapeutic (131)I activity. The segmentation method's lower volume limit of determinability was a sphere of 0.80 mL, which classified the lesions into a known-volume group (>0.80 mL) or a small-volume group (≤0.80 mL) with their respective average and minimum ADs. The posttherapy PET data were used to assess the lesion-based therapy success. In the known-volume group, the response rate was calculated on the basis of lesions that received average ADs above the generally accepted threshold of 85 Gy for metastases and 300 Gy for thyroid remnants (TRs) and was expressed as the percentage of completely responding lesions. In the small-volume group, the metastasis and TR responses were evaluated for 3 minimum-AD groups: 5 to 10 Gy (TR, 5 to 30 Gy), >10 to 85 Gy (TR, >30 to 300 Gy), and >85 Gy (TR, >300 Gy). Their response rates were calculated in terms of the percentage of completely responding lesions in each minimum-AD group. RESULTS: In total, 59 lesions in 17 patients were amenable to reliable volume estimation. The response rates were 63%, 88%, and 90% for lymph node metastases (LMs), pulmonary metastases, and TRs, respectively. The response rates of 168 small lesions in 34 patients were more than 82% for LMs and more than 91% for TRs in each of the 3 minimum-AD groups; all small pulmonary metastases responded completely. CONCLUSION: In the known-volume group, the response rate for TRs matched well with historical data derived using (131)I scintigraphy imaging, whereas the response rate for LMs was not as high as expected, which may be explained by too short a follow-up time for a few LMs and a higher sensitivity of PET imaging. Small lesions were treated effectively, suggesting that they are considerably smaller than 0.80 mL.
UNLABELLED: (124)I PET/CT images from differentiated thyroid cancerpatients were retrospectively analyzed to assess the relationship between absorbed radiation dose (AD) to lesions and their response after radioiodine therapy. METHODS:Patients received serial (124)I PET/CT scans before and after their first radioiodine treatment. The pretherapy PET data were used to segment the lesion volumes and to predict the therapy-delivered ADs after administration of the therapeutic (131)I activity. The segmentation method's lower volume limit of determinability was a sphere of 0.80 mL, which classified the lesions into a known-volume group (>0.80 mL) or a small-volume group (≤0.80 mL) with their respective average and minimum ADs. The posttherapy PET data were used to assess the lesion-based therapy success. In the known-volume group, the response rate was calculated on the basis of lesions that received average ADs above the generally accepted threshold of 85 Gy for metastases and 300 Gy for thyroid remnants (TRs) and was expressed as the percentage of completely responding lesions. In the small-volume group, the metastasis and TR responses were evaluated for 3 minimum-AD groups: 5 to 10 Gy (TR, 5 to 30 Gy), >10 to 85 Gy (TR, >30 to 300 Gy), and >85 Gy (TR, >300 Gy). Their response rates were calculated in terms of the percentage of completely responding lesions in each minimum-AD group. RESULTS: In total, 59 lesions in 17 patients were amenable to reliable volume estimation. The response rates were 63%, 88%, and 90% for lymph node metastases (LMs), pulmonary metastases, and TRs, respectively. The response rates of 168 small lesions in 34 patients were more than 82% for LMs and more than 91% for TRs in each of the 3 minimum-AD groups; all small pulmonary metastases responded completely. CONCLUSION: In the known-volume group, the response rate for TRs matched well with historical data derived using (131)I scintigraphy imaging, whereas the response rate for LMs was not as high as expected, which may be explained by too short a follow-up time for a few LMs and a higher sensitivity of PET imaging. Small lesions were treated effectively, suggesting that they are considerably smaller than 0.80 mL.
Authors: Frederik A Verburg; Markus Luster; Luca Giovanella; Michael Lassmann; Carlo Chiesa; Nicolas Chouin; Glenn Flux Journal: Eur J Nucl Med Mol Imaging Date: 2017-02-16 Impact factor: 9.236
Authors: Laurent Dercle; Désirée Deandreis; Marie Terroir; Sophie Leboulleux; Jean Lumbroso; Martin Schlumberger Journal: Eur J Nucl Med Mol Imaging Date: 2016-06 Impact factor: 9.236
Authors: I Binse; T D Poeppel; M Ruhlmann; B Gomez; L Umutlu; A Bockisch; S J Rosenbaum-Krumme Journal: Eur J Nucl Med Mol Imaging Date: 2015-12-19 Impact factor: 9.236
Authors: Hong Grafe; Maike E Lindemann; Manuel Weber; Julian Kirchner; Ina Binse; Lale Umutlu; Ken Herrmann; Harald H Quick Journal: Cancers (Basel) Date: 2022-06-21 Impact factor: 6.575
Authors: Seong Young Kwon; Sang-Woo Lee; Eun Jung Kong; Keunyoung Kim; Byung Il Kim; Jahae Kim; Heeyoung Kim; Seol Hoon Park; Jisun Park; Hye Lim Park; So Won Oh; Kyoung Sook Won; Young Hoon Ryu; Joon-Kee Yoon; Soo Jin Lee; Jong Jin Lee; Ari Chong; Young Jin Jeong; Ju Hye Jeong; Young Seok Cho; Arthur Cho; Gi Jeong Cheon; Eun Kyoung Choi; Jae Pil Hwang; Sang Kyun Bae Journal: Eur J Nucl Med Mol Imaging Date: 2019-12-10 Impact factor: 9.236
Authors: Donika Plyku; Robert F Hobbs; Di Wu; Carlos Garcia; George Sgouros; Douglas Van Nostrand Journal: Ann Nucl Med Date: 2022-02-04 Impact factor: 2.668
Authors: Walter Jentzen; Jinda Phaosricharoen; Benedikt Gomez; Philipp Hetkamp; Vanessa Stebner; Ina Binse; Sonja Kinner; Ken Herrmann; Amir Sabet; James Nagarajah Journal: EJNMMI Phys Date: 2018-07-19
Authors: Jakob W Kist; Manfred van der Vlies; Otto S Hoekstra; Henri N J M Greuter; Bart de Keizer; Marcel P M Stokkel; Wouter V Vogel; Marc C Huisman; Arthur van Lingen Journal: EJNMMI Res Date: 2016-04-27 Impact factor: 3.138